Serotonin Syndrome: Fairly Common but Frequently Forgotten

Awad Magbri, MD, FACP*, Mariam El-Magbri, BSC, MPH, Kamran Suljuki, Pharm D, MBA, and Darcy Rose, RN

Toledo Vascular Access Center, Toledo Clinic Inc, USA

Abstract

The authors presented a case of serotonin syndrome cause by drug interaction. The patient is presented with classical features of the syndrome with hyper-excitability, tremor, change in mental status, and low grade fever. The patient made uneventful recovery after the stoppage of the offending drugs. This case calls for the clinicians to be vigilant of the drug interaction that can cause unintended side effects to the patient under their care.

Keywords

Serotonin syndrome, Hyper-excitability, Autonomic hyperactivity, Tremor

Case History

A 72-year-old Caucasian man has past medical history of hypertension, type-2 diabetes mellitus, peripheral vascular disease, hyperlipidemia, and anxiety-depression mood. He was admitted to the hospital secondary to fall which resulted into left neck of femur fracture. He underwent successful open reduction and internal fixation. He was on escitalopram and bupropion hydrochloride before the surgery for his anxiety/depression. He was treated with tramadol by the orthopedic surgeon for his postoperative pain. The patient was transferred to long-term acute care facility (LTAC) for continuation of his medical management and rehabilitation. Postoperatively, about three days later he started having agitation, tremor of his hands, and hyper-excitability with hyperreflexia, confusion and low grade fever. These symptoms were attributed to serotonin syndrome, and they resolved only when escitalopram, bupropion, and tramadol were stopped. The hospital course of the patient made uneventful recovery after the stoppage of the offending drugs. This case calls for the clinicians to be vigilant of the drug interaction that can cause unintended side effects to the patient under their care.

In the LTAC his vital signs were, blood pressure 161/85 mmHg, heart rate of 103/min regular, respiratory rate 20/min, temperature of 99.8 F, and oxygen saturation was 98% on 3 L nasal cannula. He demonstrated clear encephalopathic picture with agitation, tremor, confusion, and hyper-reflexia with ankle clonus bilaterally. His pupils were dilated with sluggish reaction to light, but ocular clonus could not be elicited. His respiratory system examination was unremarkable. His abdominal examination reveals no tenderness, masses or hepato-splenomegaly. However, his bowel sounds were hyperactive. His surgical wound was clean with no signs of infection and his lower limb examination showed only stasis dermatitis with no tenderness or edema. Magnetic resonance imaging of the brain for perfusion (MRI-perfusion) study was not performed. Upon admission to the hospital his laboratory data showed sodium of 142 mEq/L, potassium of 4.8 mEq/L, chloride of 100 mEq/L, bicarbonate 27 Mmol/L, blood urea nitrogen of 29 mg/L and serum creatinine of 0.92 mg/L. He was hypoglycemic with a blood sugar level of 63 mg/L with no change in his mental status after correction of his hypoglycemia. His calcium rate is of 8.9 mg/L and complete blood count showed white cell count of 7.01 with hemoglobin of 8.2 and hematocrit of 27.9, and his platelet count was 211 K/L. His blood culture and urine culture were negative.

There was no clear explanation of his acute confusional state with hyper-excitability and low grade fever which persisted even after treatment of hypoglycemia. After reviewing his medication the only new addition to his medication was tramadol. Escitalopram is a selective serotonin reuptake inhibitor and the opioid tramadol also has serotonergic effects, so the combination could result in the SS. The possibility of drug interaction with serotonin toxicity was raised and escitalopram, bupropion hydrochloride, and tramadol were stopped. The hospital course of the patient after discontinuation of his medication shows rapid improvement and returned to baseline in his physical and mental health. His confusional state had cleared slowly giving credence to the clinical diagnosis of serotonin toxicity.

*Corresponding author: Awad Magbri, MD, Toledo Vascular Access Center, Toledo Clinic Inc, Toledo, OH, USA, Tel: 815-520-8211

Accepted: March 09, 2019
Published online: March 11, 2019

Copyright: © 2019 Magbri A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Serotonin toxicity or serotonin syndrome (SS) is a life-threatening condition associated with increased serotoninergic activity in the central and peripheral nervous systems [1]. The syndrome is usually results from misuse of therapeutic medications, inadvertent drug interaction, or intentional self-poisoning [1].

Serotonin syndrome is characterized by a triad of mental status changes, neuromuscular abnormalities, and autonomic hyperactivity [1-4]. SS is a spectrum of clinical activity ranges from benign clinical findings to lethal condition [1-4]. The syndrome occurs in all age groups and the incidence of this syndrome increases with the upsurge of serotoninergic drugs [1,4,5]. The syndrome can be ascribed to overdose [6,7] and can even occurs in patients who are treated with therapeutic hypothermia after cardiac arrest [8].

The selective serotonin reuptake inhibitors (SSRI) are the most implicated drugs in SS [9]. Serotonin modulates attention, behavior, and thermoregulation in the central nervous system (CNS). In the peripheral nervous system, serotonin is produced by intestinal enterochromaffin cells and is involved in the regulation of vasoconstriction, uterine contraction, bronchospasm, and gastrointestinal motility [3]. Serotonin is also found in platelets and promotes platelet aggregation.

Serotonin syndrome can result from the following mechanisms of drugs:

1. Increases serotonin formation e.g. tryptophan.
2. Increase release of serotonin- amphetamines, cocaine, MDMA (ecstasy), levodopa, carbidopa-levodopa.
3. Impair reuptake from the synaptic cleft into the pre-synaptic neuron - cocaine, MDMA, meperidine, tramadol, pentazocine, SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g. duloxetine which can cause SS even after single dose [10], dopamine-norepinephrine reuptake inhibitors (buproprion), serotonin modulators (trazodone, vilazodone), tricyclic antidepressants (amitriptyline, clomipramine, desipramine, nortriptyline, protriptyline), 5-HT3 receptor antagonists (ondansetron), metoclopramide, valproate, carbamazepine, dextromethorphan.
4. Inhibits serotonin metabolism (i.e., inhibits monoamine oxidase activity) - MAOIs (phenelzine, selegiline, linezolid, procarbazine).
5. Direct serotonin agonist - buspirone, triptans (sumatriptan, rizatriptan), ergot derivatives (ergotamine, methylergonovine), fentanyl, LSD.
6. Increase sensitivity of postsynaptic receptors - lithium.

Stimulation of the postsynaptic 5-HT1A, and 5-HT2A receptors have been implicated in the SS [11], but any drug interaction results in the increase serotonin activity from the above mentioned mechanisms can results to SS. The interactions of MAOI with other drugs may be the most severe and often leads to adverse outcome including death in SS [12,13].

The diagnosis of SS is mainly based on clinical grounds which involves in increase of serotoninergic activity, mental status changes, anxiety, agitation, delirium, restlessness, and disorientation [14]. Autonomic manifestation of diaphoresis, tachycardia, hyperthermia, hypertension, vomiting and diarrhea [3] can be more pronounced in this syndrome. Neuromuscular hyperactivity with tremor, muscle rigidity, myoclonus, and hyperreflexia with positive Babinski sign are particularly common. Lower limbs hyperreflexia, ocular and lower limbs clonus (Video 1) and rigidity are often more noticeable [3]. The majority of SS are presented within 24-hours of change in the dose of serotoninergic drug or drug-drug interaction [3].

Laboratory evaluation- may reveal non-specific findings like elevated white blood cells, elevated creatine phosphokinase, decrease serum bicarbonate, disseminated intra-vascular coagulation, rhabdomyolysis, metabolic acidosis, renal failure, myoglobinuria, and acute respiratory distress syndrome [3].

A Diagnostic criteria is based on clinical depiction of the serotonin toxicity which can be enhanced by the use of Hunter Toxicity Criteria Decision Rules [15]. These criteria have high sensitivity and specificity (84%, 97% respectively) in a patient who has taken serotoninergic agent.

1. Spontaneous clonus
2. Inducible clonus + agitation or diaphoresis
3. Ocular clonus + agitation or diaphoresis
4. Tremor + hyperreflexia
5. Hypertonia + temperature > 38C + ocular clonus or inducible clonus

The differential diagnosis of SS includes:

1. Neuroleptic malignant syndrome (NMS)
2. Anticholinergic toxicity
3. Malignant hyperthermia
4. Sympathomimetic agent intoxication
5. Sedative-hypnotic withdrawal
6. Meningitis
7. Encephalitis

The treatment of SS consists of:

1. Discontinue serotoninergic agents
2. Sedate with benzodiazepines (lorazepam 1-2 mg IV, titrate dose to effects)
3. Provide oxygen to (maintain SPO2 > 94), IV fluids and continuous cardiac monitor
4. If benzodiazepines and supportive care fail to improve agitation and abnormal vital signs, give cyproheptadine (12 mg PO or via NGT)
5. Patients with temperature > 41.1 C with immediate sedation, paralysis, and intubation.
Back to our patient, following discontinuation of the escitalopram, bupropion hydrochloride, and tramadol, he continued to show fast clinical improvement with resolution of his symptoms within 24 hours. He continued to have physical therapy and occupational therapy with improvement in his strength and was able to put weight on the left leg. In summary, SS should be considered whenever the clinical picture suggested the possibility of SS. Missing the diagnosis of SS can have dire consequence to the patient afflicted by the disease.

References


DOI: 10.36959/832/396

Copyright: © 2019 Magbri A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.